Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 237

Results For "ENT"

9402 News Found

Single-use gloves misused across India, raising health risks
Healthcare | March 14, 2026

Single-use gloves misused across India, raising health risks

One task, one interaction, one pair, experts advocate


Wanbury bags key Brazil nod, eyes market expansion
News | March 14, 2026

Wanbury bags key Brazil nod, eyes market expansion

Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA


APL Healthcare’s Unit-IV classified as VAI by the USFDA
News | March 14, 2026

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed


Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
Drug Approval | March 13, 2026

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

Marks significant milestone for breakthrough biologic to treat rare blood cancers


Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis
Healthcare | March 12, 2026

Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis

The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab


Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues
Hospitals | March 12, 2026

Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues

The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise


Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
Clinical Trials | March 12, 2026

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36